NCT06866977Not yet recruitingPhase 1/2
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 10 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a single-center, single-arm, open label investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of advanced pancreatic cancer.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 4 Mar 2025
- Start date
- 12 Mar 2025
- Primary completion date
- 31 Oct 2025
- Lead sponsor
- Xiangya Hospital of Central South University
- Diseases
- Pancreatic cancer
- NCT number
- NCT06866977
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 10
- From 12 Mar 2025 to the primary completion date, 31 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment with other oncolytic viruses.
- Known alcohol or drug dependency.
Other illness
- Have suffered from other malignant tumors in the past 5 years, except for cured basal cell skin cancer, non-melanoma skin cancer, and cervical cancer in situ.
Other
- Immunocompromised patients.
- Women who are pregnant or breastfeeding.
Who the study is looking for
- Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.
- Males and females≥18 years of age, inclusive, at the Screening Visit.
- Have unresectable pancreatic cancer as determined by imaging or surgical exploration and locally advanced or metastatic pancreatic ductal adenocarcinoma (including adenosquamous carcinoma) as confirmed by histology or cytology.
- No prior systemic therapy for unresectable locally advanced and metastatic pancreatic cancer.
- Have at least one measurable lesion according to RECIST v1.1 criteria.
- An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
- Expected survival time of≥3 months.
- No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xiangya Hospital of Central South University Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.